QIAGEN N.V. announced a partnership with Freenome, a leading artificial intelligence (AI) genomics company, to accelerate the development and commercialization of next-generation sequencing (NGS) tests to enable precision medicine in cancer treatment.
- Introduces pipeline to reach patients more quickly with next-generation sequencing for cancer, in line with modernized regulatory approach from the U.S. Food and Drug Administration
- Announces partnership with Freenome to accelerate companion diagnostics development in immuno-oncology by combining industry-leading artificial intelligence with QIAGEN’s Sample to Insight solutions
- Showcases QIAGEN’s NGS technologies, including new panels for the GeneReader NGS System, at the 2018 ASCO Annual Meeting in Chicago
QIAGEN will discuss this initiative and showcase its broad portfolio of Sample to Insight solutions for cancer, at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting from June 1-5, 2018, in Chicago.
QIAGEN is partnering with Freenome to accelerate companion diagnostics development in immuno-oncology by pairing industry-leading artificial intelligence with QIAGEN’s Sample to Insight solutions. QIAGEN and Freenome will co-market the two partners’ solutions to provide pharmaceutical companies with access to machine learning insights from a broad range of biological signals, augmenting in-house bioinformatics and QIAGEN solutions. The collaboration is addressing the need for faster, more accurate and sophisticated molecular diagnostic tests that predict whether a patient will benefit from immuno-oncology therapies.
The full press release can be found here
View source version on businesswire.com: https://www.businesswire.com/news/home/20180531006429/en/
Contacts
QIAGEN
Investor Relations
John Gilardi, +49 2103 29 11711
ir@QIAGEN.com
or
Public Relations
Robert Reitze, +49 2103 29 11676
pr@QIAGEN.com
or
Freenome
Lena Cheng, MD - +1 650-822-7962
press@freenome.com
